Sugi Predict

Sugi Predict / Compounds / SCHEMBL3512016

SCHEMBL3512016

SCHEMBL3512016

COCC1CCCN1C(=O)OC(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.43
▸ ALOX5AP P20292 1/20 0.43
▸ FEN1 P39748 1/20 0.43
▸ PDE8B O95263 1/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ ATM Q13315 2/20 0.41
▸ OPRD1 P41143 1/20 0.41
▸ DPP4 P27487 1/20 0.41
▸ DPP8 Q6V1X1 1/20 0.41
▸ TSHR P16473 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3512019 1.00 HSD17B10 (0.47) HSD17B10SMN1; SMN2ALDH1A1ALOX5APFEN1
SCHEMBL792043 1.00 HSD17B10 (0.47) HSD17B10SMN1; SMN2ALDH1A1ALOX5APFEN1
SCHEMBL5307883 0.95 PDE8B (0.46) HSD17B10SMN1; SMN2ALDH1A1ALOX5APFEN1
SCHEMBL12485875 0.95 PDE8B (0.46) HSD17B10SMN1; SMN2ALDH1A1ALOX5APFEN1
SCHEMBL5257475 0.95 PDE8B (0.46) HSD17B10SMN1; SMN2ALDH1A1ALOX5APFEN1
SCHEMBL4177435 0.90 HSD17B10 (0.40) HSD17B10SMN1; SMN2ALDH1A1ATM
SCHEMBL4177439 0.90 HSD17B10 (0.40) HSD17B10SMN1; SMN2ALDH1A1ATM
SCHEMBL70260 0.90 HSD17B10 (0.40) HSD17B10SMN1; SMN2ALDH1A1ATM
SCHEMBL21122413 0.88 HSD17B10 (0.47) HSD17B10SMN1; SMN2ALDH1A1ALOX5APFEN1
SCHEMBL24251932 0.87 DPP4 (0.39) HSD17B10ALDH1A1ALOX5APFEN1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111943879-A (3S, 4R) 3-amino-4 (methoxymethyl) pyrrolidine-1-tert-butyl formate and synthetic method thereof 南通大学 2020-11-17 — — CN claimed
CN-117916238-A Compositions and methods for inhibiting RAS 瑟拉斯有限公司 2024-04-19 — — CN disclosed
CN-117597120-A Spiroindolone compounds as Kv1.3 potassium Shaker channel blockers D·E·萧尔研究有限责任公司 2024-02-23 — — CN disclosed
CN-116096707-A Inhibitors of fibroblast growth factor receptor kinase 金耐特生物制药公司 2023-05-09 — — CN disclosed
CN-116057045-A Fibroblast growth factor receptor kinase inhibitors 金耐特生物制药公司 2023-05-02 — — CN disclosed
EP-4169922-A1 FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2023-04-26 — — EP disclosed
WO-2022033532-A1 FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海和誉生物医药科技有限公司 2022-02-17 — — WO disclosed
CN-111943879-A (3S, 4R) 3-amino-4 (methoxymethyl) pyrrolidine-1-tert-butyl formate and synthetic method thereof 南通大学 2020-11-17 — — CN disclosed
CN-109071563-A Inhibitors of bruton's tyrosine kinase and methods of use thereof 詹森药业有限公司 2018-12-21 — — CN disclosed
US-9617282-B2 Macrocyclic compounds as IRAK4 inhibitors for the treatment of inflammatory diseases BIOGEN MA INC. (US) 2017-04-11 — — US disclosed
EP-2205596-A1 (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING COMENTIS, INC. (US) 2010-07-14 — — EP disclosed
US-20090156574-A1 2-ACYLAMINO-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2009-06-18 — — US disclosed
US-20090156574-A1 2-ACYLAMINO-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2009-06-18 — — US disclosed
WO-2009042694-A1 (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING COMENTIS, INC. (US) 2009-04-02 — — WO disclosed
US-7504511-B2 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof SANOFI-AVENTIS (FR) 2009-03-17 — — US disclosed
US-7504511-B2 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof SANOFI-AVENTIS (FR) 2009-03-17 — — US disclosed
US-20080027035-A1 Dpp-Iv Inhibitors GRAFFINITY PHARMACEUTICALS AG (DE) 2008-01-31 — — US disclosed
EP-1613304-B1 DPP-IV INHIBITORS SANTHERA PHARMACEUTICALS CH (CH) 2007-09-12 — — EP disclosed
EP-1613304-A1 DPP-IV INHIBITORS Graffinity Pharmaceuticals Aktiengesellschaft (DE) 2006-01-11 — — EP disclosed
WO-2005056003-A1 DPP-IV INHIBITORS SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2005-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027035-A1 Dpp-Iv Inhibitors DPP4, DPP7, DPP3 HSD17B10 1240/4885SMN1; SMN2 3927/4885ALDH1A1 376/4885
US-20090156574-A1 2-ACYLAMINO-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF PAH, ABAT, AADAT HSD17B10 401/4885SMN1; SMN2 2072/4885ALDH1A1 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.